THIS ANNOUNCEMENT IS RESTRICTED AND
IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF
SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE,
PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION
PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY
JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS
ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU)
NO. 596/2014 (AS AMENDED) AS IT FORMS PART OF THE DOMESTIC LAW OF
THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT
2018 (AS AMENDED) ("MAR").
FOR IMMEDIATE RELEASE
25 February 2025
One Health Group
plc
("One
Health" or the "Company")
Result of WRAP Retail
Offer
One Health Group plc (AQSE: OHGR), a
provider of NHS-funded medical procedures, is pleased to announce
that, further to the announcement made on 19 February regarding the
proposed Retail Offer (the "Retail
Offer Launch Announcement"), and following the closing of
the Retail Offer on 24 February 2025, the Company has conditionally
raised approximately £0.2 million in the Retail Offer through the
issue of 97,939 Retail Offer Shares at the Issue Price of 180 pence
per share.
The Retail Offer is conditional
upon, inter alia,
completion of the Placing, Cancellation and Admission.
The Company also announced a Placing
and Open Offer (together with the Retail Offer, the "Capital Raising"). In aggregate, the
Placing and Retail Offer have raised gross proceeds of
approximately £7.5 million, via the issue of 2,888,888 New Placing
Shares and 97,939 Retail Offer Shares, in addition to the sale of
1,194,721 Sale Shares held by the Selling Shareholders.
The Open Offer, to raise additional
gross proceeds of up to a maximum of approximately £0.5 million
(before expenses), is being provided by the Company in order to
provide Qualifying Shareholders who have not taken part in the
Placing with an opportunity to participate in the Capital Raising.
The Open Offer remains open for valid applications until 11.00 a.m.
on 6 March. For more detail and information, please refer to the
Circular posted to Shareholders on 20 February 2025 and available
on the Company's website: www.onehealth.co.uk/investors.
Admission and Total Voting Rights
As set out in the Retail Offer
Launch Announcement, the Company intends to cancel the admission of
the Existing Ordinary Shares to trading on the AQSE Growth Market,
and an application will be made for the New Ordinary Shares and the
Existing Ordinary Shares to be admitted to trading on AIM, which
remains subject to the passing of certain resolutions at a general
meeting of the Company to be held at 131
Psalter Lane, Sheffield, South Yorkshire, S11 8UX at 10.00 a.m. on
10 March 2025.
Admission is expected to commence at
8:00 a.m. on 20 March 2025 (or such later time and/or date as may
be agreed between the Company and Panmure Liberum, being no later
than the Long Stop Date).
Upon Admission, and assuming full
uptake of the Open Offer, the Enlarged
Share Capital is expected to be 13,814,554 Ordinary Shares. On this
basis, the New Ordinary Shares will represent approximately 23.6
per cent. of the Enlarged Share Capital.
The New Ordinary Shares will, when
issued, be credited as fully paid and will be issued subject to the
Company's articles of association and will rank pari passu in all respects with the
Existing Ordinary Shares.
Terms used but not defined in this announcement have the same
meaning as set out in the Company's announcement released at 7:00
a.m. on 19 February 2025.
For
more information, please contact:
One
Health Group plc
Derek Bickerstaff,
Chairman
Adam Binns, CEO
|
via
Square1 Consulting
|
Panmure Liberum (Corporate Adviser, Nominated Adviser and Sole
Bookrunner)
Emma Earl, Will Goode, Mark Rogers,
Joshua Borlant
Rupert Dearden
|
Tel: +44
(0) 20 3100 2000
|
Winterflood Retail Access Platform
Joe Winkley
Sophia Bechev
|
WRAP@winterflood.com
+44(0) 20
3100 0286
|
Square1 Consulting
David
Bick
|
Tel: +44
207 929 5599
+44 7831
381201
|
|
|
Further information on the Company
can be found on its website at www.onehealth.co.uk.
The Company's LEI is
984500DC689F5BAD8732.
This announcement should be read in
its entirety. In particular, the information in the "Important Notices" section of the
announcement should be read and understood.
Important Notices
The content of this announcement,
has been prepared by and is the sole responsibility of the
Company.
The release, publication or
distribution of this announcement may be restricted by law in
certain jurisdictions and persons into whose possession any
document or other information referred to herein comes should
inform themselves about and observe any such restriction. Any
failure to comply with these restrictions may constitute a
violation of the securities laws of any such
jurisdiction.
This announcement and the
information contained herein is not for release, publication or
distribution, directly or indirectly, in whole or in part, in or
into or from the United States (including its territories and
possessions, any state of the United States and the District of
Columbia (the "United
States" or "US")),
Australia, Canada, New Zealand, Japan, the Republic of South
Africa, any member state of the EEA or any other jurisdiction where
to do so might constitute a violation of the relevant laws or
regulations of such jurisdiction.
The Ordinary Shares have not been
and will not be registered under the US Securities Act of 1933, as
amended (the "US Securities
Act") or under the applicable state securities laws of the
United States and may not be offered or sold directly or indirectly
in or into the United States. No public offering of the Ordinary
Shares is being made in the United States. The Ordinary Shares are
being offered and sold outside the United States in "offshore transactions", as defined in,
and in compliance with, Regulation S under the US Securities Act
("Regulation S") to non-US
persons (within the meaning of Regulation S). In addition, the
Company has not been, and will not be, registered under the US
Investment Company Act of 1940, as amended.
This announcement does not
constitute an offer to sell or issue or a solicitation of an offer
to buy or subscribe for Ordinary Shares in the United States,
Australia, Canada, New Zealand, Japan, the Republic of South
Africa, any member state of the EEA or any other jurisdiction in
which such offer or solicitation is or may be unlawful. No public
offer of the securities referred to herein is being made in any
such jurisdiction.
This announcement is not for
publication or distribution, directly or indirectly, in or into the
United States of America. This announcement is not an offer
of securities for sale into the United States. The securities
referred to herein have not been and will not be registered under
the US Securities Act, and may not be offered or sold in the United
States, except pursuant to an applicable exemption from
registration. No public offering of securities is being made
in the United States.
WRAP is a proprietary technology
platform owned and operated by Winterflood (registered address at
Riverbank House, 2 Swan Lane, London EC4R 3GA; FRN 141455).
Winterflood is authorised and regulated in the United Kingdom by
the Financial Conduct Authority, is acting exclusively for the
Company and for no-one else and will not regard any other person
(whether or not a recipient of this announcement) as its client in
relation to the Retail Offer and will not be responsible to anyone
other than the Company for providing the protections afforded to
its clients, nor for providing advice in connection with the Retail
Offer, Admission and the other arrangements referred to in this
announcement.
AIM
is a market designed primarily for emerging or smaller companies to
which a higher investment risk tends to be attached than to larger
or more established companies. AIM securities are not admitted to
the Official List of the Financial Conduct Authority . An investment
in the Company may not be suitable for all recipients of this
document. Any such investment is speculative and
involves a high degree of risk.
Prospective investors should carefully consider whether an
investment in the Company is suitable for them in light of their circumstances
and the
financial resources
available to
them.
The
value of Ordinary Shares and the income from them is not guaranteed
and can fall as well as rise due to stock market movements. When
you sell your investment, you may get back less than you originally
invested. Figures refer to past performance and past performance is
not a reliable indicator of future results.
Returns may increase or decrease as a result of
currency fluctuations.
Certain statements in this
announcement are forward-looking statements which are based on the
Company's expectations, intentions and projections regarding its
future performance, anticipated events or trends and other matters
that are not historical facts. These forward-looking statements,
which may use words such as "aim", "anticipate", "believe",
"intend", "estimate", "expect" and words of similar meaning,
include all matters that are not historical facts. These
forward-looking statements involve risks, assumptions and
uncertainties that could cause the actual results of operations,
financial condition, liquidity and dividend policy and the
development of the industries in which the Company's businesses
operate to differ materially from the impression created by the
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties and other factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. Given those risks and uncertainties,
prospective investors are cautioned not to place undue reliance on
forward-looking statements.
These forward-looking statements
speak only as at the date of this announcement and cannot be relied
upon as a guide to future performance. The Company and Winterflood
expressly disclaim any obligation or undertaking to update or
revise any forward-looking statements contained herein to reflect
actual results or any change in the assumptions, conditions or
circumstances on which any such statements are based unless
required to do so by the FCA, the London Stock Exchange or
applicable law.
The information in this announcement
is for background purposes only and does not purport to be full or
complete. None of Winterflood or any of its affiliates, accepts any
responsibility or liability whatsoever for, or makes any
representation or warranty, express or implied, as to this
announcement, including the truth, accuracy or completeness of the
information in this announcement (or whether any information has
been omitted from the announcement) or any other information
relating to the Company or associated companies, whether written,
oral or in a visual or electronic form, and howsoever transmitted
or made available or for any loss howsoever arising from any use of
the announcement or its contents or otherwise arising in connection
therewith. Winterflood and its affiliates, accordingly disclaim all
and any liability whether arising in tort, contract or otherwise
which they might otherwise be found to have in respect of this
announcement or its contents or otherwise arising in connection
therewith.
Any indication in this announcement
of the price at which the Ordinary Share have been bought or sold
in the past cannot be relied upon as a guide to future performance.
Persons needing advice should consult an independent financial
adviser. No statement in this announcement is intended to be a
profit forecast and no statement in this announcement should be
interpreted to mean that earnings or a target dividend per share of
the Company for the current or future financial years would
necessarily match or exceed the historical published earnings or
dividends per share of the Company.
Neither the content of the Company's
website (or any other website) nor the content of any website
accessible from hyperlinks on the Company's website (or any other
website) is incorporated into or forms part of this announcement.
The Ordinary Shares to be issued or sold pursuant to the Retail
Offer will not be admitted to trading on any stock exchange other
than AIM, the market of that name operated by the London Stock
Exchange.
Panmure Liberum Limited, which is
authorised and regulated by the FCA in the United Kingdom, is
acting as Nominated Adviser and sole broker to the Company in
connection with the Placing. Panmure Liberum Limited has not
authorised the contents of, or any part of, this announcement, and
no liability whatsoever is accepted by Panmure Liberum Limited
or any of its affiliates or agents or its or
their directors, officers, partners, employees, agents or
advisersfor the accuracy of any information or opinions
contained in this announcement or for the omission of any material
information. No representation or warranty, express or implied, is
or will be made as to, or in relation to, and no responsibility or
liability is or will be accepted by Panmure Liberum Limited or by
any of its affiliates or agents or its or
their directors, officers, partners,
employees, agents or advisersas to, or in relation to, the
accuracy or completeness of this announcement or any other written
or oral information made available to or publicly available to any
interested party or its advisers, and any liability therefor is
expressly disclaimed. The responsibilities of Panmure Liberum
Limited as the Company's Nominated Adviser under the AIM Rules
for Companies and the AIM Rules for Nominated Advisers are owed
solely to London Stock Exchange plc and are not owed to the Company
or to any director or shareholder of the Company or any other
person, in respect of its decision to acquire shares in the capital
of the Company in reliance on any part of this announcement, or
otherwise.